The Ethics of Thrombolytic Trials Beyond 3 (or 4.5) Hours: Randomized Controlled Trials Are Required to Change Clinical Practice
Stroke 40:1545, Donnan,G.A. &Davis,S.M., 2009
Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
NEJM 376:209-220,280, Montalban, X.,et al, 2017
Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis
NEJM 367:1098-1106,1149, Gold, R.,et al, 2012
Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis
NEJM 367:1087-1097,1149, Fox, R.J.,et al, 2012
Use of Placebo Surgery in Controlled Trials of a Cellular-Based Therapy for Parkinson's Disease
NEJM 341:988-992, Freeman,T.B.,et al, 1999
Streptokinase for Acute Ischemic Stroke with Relationship to Time of Administration
JAMA 276:961-966, 9951996., Donnan,G.A.,et al, 1996